Zembrace Symtouch was Tonix Pharmaceuticals Holding’s largest product and service line in fiscal 2025, bringing in $9.31M of $13.11M (71%).
| Product and Service | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| Zembrace Symtouch | $6.30M | $8.55M | $9.31M |
| Tosymra | $1.46M | $1.55M | $2.37M |
| Tonmya | — | — | $1.42M |
| Total | $7.77M | $10.09M | $13.11M |
Tonix Pharmaceuticals Holding brought in $13.11M from its three product and service lines in fiscal 2025, the year ended December 31, 2025. Tonix Pharmaceuticals Holding regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $10.09M. Zembrace Symtouch was the largest at $9.31M (71.1%), ahead of Tosymra at $2.37M (18.1%) and Tonmya at $1.42M (10.8%).
Compared with fiscal 2024, Tosymra grew 53.2% to $2.37M and Zembrace Symtouch grew 9.0% to $9.31M.
Tonix Pharmaceuticals Holding began breaking out Tonmya in fiscal 2025, when it brought in $1.42M.
Tonix Pharmaceuticals Holding (TNXP) reports its revenue by product and service. In fiscal 2025, Zembrace Symtouch was its largest product and service line, bringing in $9.31M (71.1% of the total), followed by Tosymra at $2.37M (18.1%).
Zembrace Symtouch was Tonix Pharmaceuticals Holding's largest product and service line in fiscal 2025, bringing in $9.31M, or 71.1% of the $13.11M total across its three product and service lines.
Every figure comes from Tonix Pharmaceuticals Holding's annual financial filings, as reported. Each line keeps the name Tonix Pharmaceuticals Holding gives it, and years follow its fiscal calendar.
Tonix Pharmaceuticals Holding's revenue by product and service goes back to fiscal 2023, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.